ATLANTA–Virios Therapeutics, Inc., a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $30 million, before deducting underwriting discounts, commissions and offering expenses.
In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 450,000 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments.
The shares are expected to begin trading on the Nasdaq Capital Market on December 17, 2020 under the ticker symbol “VIRI.” The offering is expected to close on December 21, 2020, subject to satisfaction of customary closing conditions.
ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.
A registration statement on Form S-1 (File No. 333-248447) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on December 16, 2020. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at prospectus@think-equity.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
